MARKET

XGN

XGN

Exagen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.28
-0.22
-1.76%
Closed 16:00 07/29 EDT
OPEN
12.37
PREV CLOSE
12.50
HIGH
12.45
LOW
12.00
VOLUME
34.51K
TURNOVER
--
52 WEEK HIGH
24.67
52 WEEK LOW
10.31
MARKET CAP
207.88M
P/E (TTM)
-9.0334
1D
5D
1M
3M
1Y
5Y
Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference, which takes place August 10-12, 2021. Ron ...
GlobeNewswire · 22h ago
Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the market close on Monday, August 9, 2021. Ron Rocca, Exag...
GlobeNewswire · 3d ago
Earnings Preview: Exagen Inc. (XGN) Q2 Earnings Expected to Decline
Zacks.com · 07/20 19:02
Is Exagen (NASDAQ:XGN) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 07/15 11:04
Exagen highlights promising data from AVISE lupus test study
Exagen (XGN) announces that its lupus test showed promise in a multi-center study in patients suspected of the disease.AVISE lupus test showed "statistically significant" clinical utility in achieving a definitive
Seekingalpha · 07/13 20:16
Exagen Announces AVISE Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupus & Science Medicine, found
Benzinga · 07/13 20:11
WorkWave launches as standalone portfolio company following separation from IFS and announces transformational add-ons
EQT is pleased to announce that WorkWave (the "Company") will become a standalone portfolio company of the EQT VIII and EQT IX funds ("EQT Private Equity'') following its separation from IFS, a global provider of enterprise software focused on the moment o...
PR Newswire · 06/22 13:25
Return On Capital Employed Overview: Exagen
In Q1, Exagen (NASDAQ:XGN) posted sales of $10.59 million. Earnings were up 101.63%, but Exagen still reported an overall loss of $5.57 million. In Q4, Exagen brought in $12.67 million in sales but lost $2.76 million in earnings.
Benzinga · 06/18 14:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XGN. Analyze the recent business situations of Exagen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XGN stock price target is 26.20 with a high estimate of 33.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 9.02M
% Owned: 53.30%
Shares Outstanding: 16.93M
TypeInstitutionsShares
Increased
17
1.68M
New
24
2.85M
Decreased
10
17.65K
Sold Out
3
53.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.75%
Healthcare Providers & Services
+0.54%
Key Executives
Non-Executive Chairman/Independent Director
Brian Birk
President/Chief Executive Officer/Director
Fortunato Rocca
Chief Financial Officer/Secretary
Kamal Adawi
Chief Operating Officer
Mark Hazeltine
Other
Debra Zack
Independent Director
Wendy Johnson
Independent Director
Tina Nova
Independent Director
Ebetuel Pallares
Independent Director
Bruce Robertson
Independent Director
James Tullis
No Data
About XGN
Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis and monitoring of autoimmune conditions. Its diagnostic tests include AVISE connective tissue disease (CTD), AVISE Lupus and AVISE antiphospholipid syndrome (APS). Its prognostic tests include AVISE systemic lupus erythematosus (SLE) Prognostic, AVISE Platelet-bound C4d (PC4d) and AVISE Anti- carbamylated proteins (CarP). Its monitoring tests include AVISE SLE Monitor, AVISE methotrexate (MTX) and AVISE hydroxychloroquine (HCQ).

Webull offers kinds of Exagen Inc stock information, including NASDAQ:XGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XGN stock methods without spending real money on the virtual paper trading platform.